(S020) Availability of Single-Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Life Care Within the Veterans Healthcare Administration

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

Single-fraction palliative radiotherapy for bone metastasis appears to be much more available for cancer patients receiving end-of-life care within the United Veterans Healthcare Administration when compared with the general US health care system.

Drew Moghanaki, MD, MPH, Alice Cheuk, MD, Helen Fosmire, MD, Mitchell Anscher, MD, Michael Hagan, MD, PhD, Stephe Lutz, MD, George Dawson, MD; United States Department of Veterans Affairs

Background: Recent surveys have demonstrated that < 20% of US-based radiation oncologists are willing to offer single-fraction palliative radiotherapy for bone metastasis. The United Veterans Healthcare Administration (VHA) initiated this study to determine the willingness of radiation oncologists who work within the VHA to offer single-fraction treatment.

Methods: In early 2013, a 12-question survey was emailed to all 78 radiation oncologists currently practicing at VHA radiation oncology facilities. Phone calls were made to nonresponders. Radiation oncologists who did not offer single-fraction palliative radiotherapy were evaluated by Fisher’s exact test for associations with a variety of factors.

Results: The response rate was 90% (70/78). Half were full-time employees of the VHA, and the majority had thoroughly read either the American College of Radiology (ACR) or American Society for Radiation Oncology (ASTRO) guidelines for palliative radiotherapy of bone metastases. Single-fraction palliative radiotherapy for bone metastasis is currently offered by 75.7% of respondents. Those not offering single-fraction palliative radiotherapy (24.3%) were more likely to be > 10 years out of training (37% vs 10%; P = .01) and more likely to have worked in private practice at some point in their career (36% vs 12%; P = .03). There were no associations with employment status, history of an academic appointment, or whether they had read the ACR or ASTRO guidelines.

Conclusion: Single-fraction palliative radiotherapy for bone metastasis appears to be much more available for cancer patients receiving end-of-life care within the VHA when compared with the general US health care system.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content